| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 35.25 | % |
| Activity | = | 101.5 | % |
| Activity | = | 77.77 | % |
| Activity | = | 53.59 | % |
| Activity | = | 66.55 | % |
| Activity | = | 87.52 | % |
| Activity | = | 62.75 | % |
| Activity | = | 70.1 | % |
| Activity | = | 46.03 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 57.29 | % |
| Activity | = | 76.13 | % |
| Activity | = | 69.46 | % |
| Activity | = | 75.17 | % |
| Activity | = | 52.41 | % |
| Activity | = | 68.16 | % |
| Activity | = | 66.47 | % |
| Activity | = | 69.05 | % |
| Activity | = | 62.44 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 66.2 | % |
| Activity | = | 66.1 | % |
| Activity | = | 62.56 | % |
| Activity | = | 74.06 | % |
| Activity | = | 66.05 | % |
| Activity | = | 63.89 | % |
| Activity | = | 64.15 | % |
| Activity | = | 67.39 | % |
| Activity | = | 54.34 | % |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Dose-Dependent Effect |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 7 | % |
| Inhibition | = | 7 | % |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |
| Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|
| MIC | = | 0.06 | ug.mL-1 | |
| MIC | = | 50 | ug.mL-1 | |
| MIC | = | 25 | ug.mL-1 | |
| MIC | = | 100 | ug.mL-1 | |
| MIC | = | 200 | ug.mL-1 | |
| MIC | = | 200 | ug.mL-1 | |
| MIC | = | 1.56 | ug.mL-1 | |
| MIC | = | 2.5 | ug.mL-1 | |
| MIC | = | 25 | ug.mL-1 | |
| MIC | = | 100 | ug.mL-1 | |
| MIC | = | 200 | ug.mL-1 | |
| MIC | = | 100 | ug.mL-1 | |
| MIC | = | 12.5 | ug.mL-1 | |
| MIC | = | 25 | ug.mL-1 | |
| MIC | = | 25 | ug.mL-1 | |
| MIC | = | 200 | ug.mL-1 | |
| MIC | = | 50 | ug.mL-1 | |
| MIC | = | 0.004 | ug.mL-1 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 12 | EC50 | = | 12000 | nM | |
| 4.5 | EC50 | = | 4500 | nM | |
| 3.4 | EC50 | = | 3400 | nM | |
| 2.7 | EC50 | = | 2700 | nM | |
| 2.9 | EC50 | = | 2900 | nM | |
| 19 | EC50 | = | 19000 | nM | |
| 2.2 | EC50 | = | 2200 | nM | |
| 1.2 | EC50 | = | 1200 | nM | |
| 0.58 | EC50 | = | 580 | nM | |
| EC50 | Not Determined | ||||
| 5.1 | EC50 | = | 5100 | nM | |
| 7.8 | EC50 | = | 7800 | nM | |
| 4.7 | EC50 | = | 4700 | nM | |
| EC50 | ND(Insoluble) | ||||
| 1.7 | EC50 | = | 1700 | nM | |
| 0.023 | EC50 | = | 23 | nM | |
| 2.2 | EC50 | = | 2200 | nM | |
| 0.1 | EC50 | = | 100 | nM | |
| 12 | EC50 | = | 12000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 9.5 | EC50 | = | 9500 | nM | |
| 2.5 | EC50 | = | 2500 | nM | |
| 1.1 | EC50 | = | 1100 | nM | |
| 4.7 | EC50 | = | 4700 | nM | |
| 22 | EC50 | = | 22000 | nM | |
| 5.9 | EC50 | = | 5900 | nM | |
| 2.2 | EC50 | = | 2200 | nM | |
| 1.4 | EC50 | = | 1400 | nM | |
| 3.2 | EC50 | = | 3200 | nM | |
| 4 | EC50 | = | 4000 | nM | |
| 7.8 | EC50 | = | 7800 | nM | |
| 1.6 | EC50 | = | 1600 | nM | |
| EC50 | ND(Insoluble) | ||||
| 1.5 | EC50 | = | 1500 | nM | |
| 0.082 | EC50 | = | 82 | nM | |
| 9.7 | EC50 | = | 9700 | nM | |
| 0.22 | EC50 | = | 220 | nM | |
| 2.2 | EC50 | = | 2200 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 7.7 | EC50 | = | 7700 | nM | |
| 1.8 | EC50 | = | 1800 | nM | |
| 0.87 | EC50 | = | 870 | nM | |
| 2.5 | EC50 | = | 2500 | nM | |
| 33 | EC50 | = | 33000 | nM | |
| 4.6 | EC50 | = | 4600 | nM | |
| 1.6 | EC50 | = | 1600 | nM | |
| 1.1 | EC50 | = | 1100 | nM | |
| 2.5 | EC50 | = | 2500 | nM | |
| 2.5 | EC50 | = | 2500 | nM | |
| 3.7 | EC50 | = | 3700 | nM | |
| 1.2 | EC50 | = | 1200 | nM | |
| EC50 | ND(Insoluble) | ||||
| 1.9 | EC50 | = | 1900 | nM | |
| 0.053 | EC50 | = | 53 | nM | |
| 4.1 | EC50 | = | 4100 | nM | |
| 0.22 | EC50 | = | 220 | nM | |
| 2.4 | EC50 | = | 2400 | nM |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | tde |
| Standard Type | Activity Comment |
|---|---|
| Activity | Toxic |
| Activity | Toxic |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment | Data Validity Comment |
|---|---|---|---|---|---|---|
| 39 | EC50 | = | 39000 | nM | ||
| 36 | EC50 | = | 36000 | nM | ||
| 37 | EC50 | = | 37000 | nM | ||
| 370 | EC50 | = | 370000 | nM | Outside typical range | |
| 40 | EC50 | = | 40000 | nM | ||
| 80 | EC50 | = | 80000 | nM | ||
| 22 | EC50 | = | 22000 | nM | ||
| 220 | EC50 | = | 220000 | nM | Outside typical range | |
| 350 | EC50 | = | 350000 | nM | Outside typical range | |
| 500 | EC50 | > | 500000 | nM | Outside typical range | |
| 370 | EC50 | = | 370000 | nM | Outside typical range | |
| EC50 | ND(Insoluble) | |||||
| 150 | EC50 | = | 150000 | nM | Outside typical range | |
| 24 | EC50 | = | 24000 | nM | ||
| 76 | EC50 | = | 76000 | nM | ||
| 8.1 | EC50 | = | 8100 | nM | ||
| 270 | EC50 | = | 270000 | nM | Outside typical range |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 0.6 | IC50 | = | 600 | nM |
| 22.8 | IC50 | = | 22800 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 63 | EC50 | = | 63000 | nM | |
| 12 | EC50 | = | 12000 | nM | |
| 3.2 | EC50 | = | 3200 | nM | |
| 16 | EC50 | = | 16000 | nM | |
| 100 | EC50 | > | 100000 | nM | |
| 37 | EC50 | = | 37000 | nM | |
| 34 | EC50 | = | 34000 | nM | |
| 4.8 | EC50 | = | 4800 | nM | |
| 17 | EC50 | = | 17000 | nM | |
| 64 | EC50 | = | 64000 | nM | |
| 100 | EC50 | > | 100000 | nM | |
| 100 | EC50 | > | 100000 | nM | |
| EC50 | ND(Insoluble) | ||||
| 53 | EC50 | = | 53000 | nM | |
| 17 | EC50 | = | 17000 | nM | |
| 22 | EC50 | = | 22000 | nM | |
| 4.6 | EC50 | = | 4600 | nM | |
| 12 | EC50 | = | 12000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 72 | EC50 | = | 72000 | nM | |
| 26 | EC50 | = | 26000 | nM | |
| 4.3 | EC50 | = | 4300 | nM | |
| 33 | EC50 | = | 33000 | nM | |
| 41 | EC50 | = | 41000 | nM | |
| 37 | EC50 | = | 37000 | nM | |
| 73 | EC50 | = | 73000 | nM | |
| 7.4 | EC50 | = | 7400 | nM | |
| 100 | EC50 | > | 100000 | nM | |
| 80 | EC50 | = | 80000 | nM | |
| 20 | EC50 | = | 20000 | nM | |
| 42 | EC50 | = | 42000 | nM | |
| EC50 | ND(Insoluble) | ||||
| 100 | EC50 | > | 100000 | nM | |
| 8.9 | EC50 | = | 8900 | nM | |
| 30 | EC50 | = | 30000 | nM | |
| 2.7 | EC50 | = | 2700 | nM | |
| 5.7 | EC50 | = | 5700 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 32 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Dose-dependent effect |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 81.71 | % |
| Activity | = | 55.8 | % |
| Activity | = | 89.66 | % |
| Activity | = | 22.38 | % |
| Activity | = | 92.06 | % |
| Activity | = | 93.03 | % |
| Activity | = | 86.01 | % |
| Activity | = | 76.87 | % |
| Activity | = | 90.29 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 24.5 | % |
| Activity | = | 43.33 | % |
| Activity | = | 52.41 | % |
| Activity | = | 25.64 | % |
| Activity | = | 42.92 | % |
| Activity | = | 37.43 | % |
| Activity | = | 39.58 | % |
| Activity | = | 41.38 | % |
| Activity | = | 42.92 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 87.83 | % |
| Activity | = | 95.37 | % |
| Activity | = | 71.03 | % |
| Activity | = | 80.44 | % |
| Activity | = | 102.9 | % |
| Activity | = | 73.81 | % |
| Activity | = | 77.57 | % |
| Activity | = | 69 | % |
| Activity | = | 71.13 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 36.45 | % |
| Activity | = | 32.62 | % |
| Activity | = | 24.82 | % |
| Activity | = | 46.26 | % |
| Activity | = | 41.44 | % |
| Activity | = | 37.73 | % |
| Activity | = | 42.66 | % |
| Activity | = | 34.92 | % |
| Activity | = | 41.11 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 98.35 | % |
| Activity | = | 103.9 | % |
| Activity | = | 95.53 | % |
| Activity | = | 69.64 | % |
| Activity | = | 73.31 | % |
| Activity | = | 94.79 | % |
| Activity | = | 96.62 | % |
| Activity | = | 74.71 | % |
| Activity | = | 97.6 | % |